611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Live Near a 'Superfund' Site? Your Life Span Might Be ShorterHormone Treatments May Raise Blood Pressure in Transgender PeopleUnexplained Drop in Resting Heart Rate in Youth 'Not a Good Thing'Common MS Meds Might Be Less Effective in Black PatientsIs It Allergies or COVID? Expert Shows How to Tell the DifferenceMany Employees Have Mixed Feelings as Offices ReopenHalf of American Adults Have Now Gotten at Least One COVID Vaccine ShotWarmer Climate, More Pollen, Worse Allergies: How to Fight BackCycling During Dialysis? It Might Help PatientsPregnancy Raises the Risk for Kidney StonesU.S. Marines Study Finds Getting COVID Won't Protect Young People From ReinfectionKnow the Signs of Rare Blood Clot Linked With J & J Vaccine1 in 50 COVID Patients in ICU Will Develop a StrokeBooster Shots a Likely Reality for COVID-Vaccinated AmericansAHA News: The Link Between Structural Racism, High Blood Pressure and Black People's HealthMost Young Americans Eager to Get COVID Vaccine: PollRashes Can Occur After COVID Vaccine,  But Dermatologists Say 'Don't Worry'Even Before COVID, Many More People Died Early in U.S. Versus EuropeCOVID Plus 'Bleeding' Stroke Doubles a Patient's Death RiskLower Rates of COVID in States That Mandated Masks: StudyCDC Panel Says It Needs More Time to Study J&J Vaccine Clotting CasesOne Good Way to Help Beat COVID: ExerciseDiabetes Can Lead to Amputations, But Stem Cell Treatment Offers HopeResearch Shows Links Between Gum Disease and Alzheimer'sNo Rise in Global Suicide Rate in First Months of PandemicCloth Masks Do Make Workouts a Bit Tougher, Study FindsMany Kids Who Develop Severe COVID-Linked Syndrome Have Neurologic SymptomsBiden, Fauci Say Pause in J&J COVID Vaccine Is Sign That Safety Comes FirstAHA News: Straight Answers to Common Questions About COVID-19 VaccinesJ&J Vaccine 'Pause' Is Not Mandate Against the Shot, FDA SaysU.K. Variant Won't Trigger More Severe COVID, Studies FindNewborns Won't Get COVID Through Infected Mom's Breast Milk: StudyU.S. Health Agencies Call for Pause in J&J COVID Vaccine After 6 People Develop ClotsUrinary Incontinence Surgery Won't Raise a Woman's Cancer RiskCOVID Vaccines Trigger Protective Immune Response in Nursing Home Residents: StudyCOVID Vaccines Might Not Protect Certain Cancer PatientsHad Facial Fillers? What You Need to Know About COVID VaccinesAntibody Cocktail May Curb Infection in Unvaccinated Who Are Exposed to COVID-19Scientists Find Clues to Why AstraZeneca's Vaccine May Cause ClotsYou've Got Fungi in Your Lungs, and That's OKNon-Emergency Surgeries Are Rebounding, But Backlogs RemainPandemic Has Put Many Clinical Trials on HoldSupply of J&J COVID Vaccine to Drop 86 Percent Next WeekStressed, Exhausted: Frontline Workers Faced Big Mental Strain in PandemicNIH Starts Trial Looking at Rare Allergic Reactions to COVID VaccinesNot Just Keyboards: Many Types of Workers Can Develop Carpal TunnelBlack Women Are Dying of COVID at Much Higher Rates Than White MenTwo Vaccines Show Effectiveness Against Emerging COVID VariantsWomen More Prone to Concussion's Long-Term Harms: StudyCOVID Cases Climb in the Midwest as British Variant Takes Hold in U.S.
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Rheumatoid Arthritis Meds May Help Fight Severe COVID-19

HealthDay News
by Steven Reinberg
Updated: Feb 26th 2021

new article illustration

FRIDAY, Feb. 26, 2021 (HealthDay News) -- Rheumatoid arthritis drugs may save lives of patients hospitalized with severe cases of COVID-19, according to a groundbreaking clinical trial.

The findings, first announced in January, have now been peer-reviewed and published in a major medical journal.

"We are delighted that our full results are now published after peer review. This confirms the robustness of our findings, that tocilizumab and sarilumab can reduce deaths by nearly a quarter, in the sickest patients with COVID," said researcher Dr. Anthony Gordon, chair in anesthesia and critical care at Imperial College London, in the United Kingdom.

In the study, initially reported in November, the arthritis drugs tocilizumab (Actemra) and sarilumab (Kevzara) reduced death among critically ill COVID-19 patients by nearly 9 percentage points, or about 25%. The drugs are immune modulators called IL-6 receptor antagonists.

These drugs also shortened patients' hospital stays significantly.

"On average, patients were discharged from [intensive care units] a week earlier and [left] hospital two weeks earlier," Gordon said, noting that "several thousand patients" had already benefited from the drugs' use through the National Health Service in the United Kingdom.

"Other studies have now confirmed our results and so even more patients will continue to benefit," he said in a college news release.

Of 353 patients in the trial, some were given tocilizumab or sarilumab; others received an inactive placebo.

Thirty-six percent of patients given a placebo died, compared to 27% of patients receiving the drugs (28% for tocilizumab, 22% for sarilumab).

That means for every 12 patients treated, one life would be saved, the study authors explained.

Gordon noted that previous trials using IL-6 receptor agonists showed no clear benefit on disease progress or survival in COVID-19 patients. But those studies included patients whose illness was less severe and treatment started at different stages, he said.

"A crucial difference may be that in our study, critically ill patients were enrolled within 24 hours of starting organ support," Gordon said. "This highlights a potential early window for treatment where the sickest patients may gain the most benefit from immune modulation treatment."

The findings were published Feb. 25 in the New England Journal of Medicine.

More information

For more on COVID-19, head to the U.S. Centers for Disease Control and Prevention.

SOURCE: Imperial College London, news release, Feb. 25, 2021